Bill
S 3212
New Jersey bill restricts pharmacy benefit managers from reimbursing below acquisition costs and bans steering practices, aiming to protect pharmacy operations and patient choice.
S 3212 addresses reimbursement disputes between pharmacy benefit managers (PBMs) and pharmacies by establishing fair reimbursement standards and restricting "steering" practices that direct patients to specific pharmacies. The bill aims to prevent PBMs from using reimbursement rates below pharmacy acquisition costs and prohibits practices that financially incentivize patients to use particular pharmacies over others based on PBM financial interests rather than patient care.
Many independent and chain pharmacies report operating at losses on certain prescriptions due to PBM reimbursement rates set below their actual drug acquisition costs. These practices strain pharmacy viability, potentially reduce pharmacy access in underserved areas, and can drive small pharmacies out of business. The bill attempts to protect pharmacy operations while potentially affecting drug costs for consumers and the PBM industry's business model.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
